DNA methylation is a process in which a chemical group, known as a methyl group, is added to a DNA molecule. This methylation can change the activity of a gene, and can be inherited from parent to offspring, making it an important epigenetic mechanism. DNA methylation is essential for normal development, and is involved in many cellular processes such as gene regulation, genomic imprinting, and X-chromosome inactivation.

DNA methylation biomarker technology revolutionizes cancer diagnostics. Epigenomics develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and contribute to eradicate today’s deadliest cancer types .

Active motif is developing a platform based on their patented transposase based technologies to simplify the interrogation of chromatin, the dynamics of histone modifications, DNA methylation, transcription factor binding, as well as short and long range gene regulation by non-coding regulatory regions. Epigenomics offers the promise of predictive biomarkers of disease development, even before changes in gene expression have taken place .

Active motif is developing a platform based on their patented transposase based technologies to simplify the interrogation of chromatin, the dynamics of histone modifications, DNA methylation, transcription factor binding, as well as short and long range gene regulation by non-coding regulatory regions. Epigenomics is the “OME” connecting Genomics to Transcriptomics and Proteomics allowing a Multiomics approach to disease research .

Genpathway specializes in providing complete service solutions for the genome-wide analysis of epigenetic events, including DNA methylation, histone modification and transcriptional regulation.

Roche NimbleGen provides products and services to the life science research market.


The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents.


The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services.


Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Kainos Medicine, Inc., a clinical-stage company, researches and develops various medicines for cancers, and brain and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is under Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under Phase II clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor, enhancer of Zeste Homolog 2 inhibitor, and BRD4 inhibitor; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia.

Epigenomics is the systematic analysis of the global state of gene expression not attributable to mutational changes across the entire genome. Epigenetic mechanisms are affected by external factors including development in utero and in childhood, environmental chemicals, drugs and pharmaceuticals, aging, and diet. Active motif’s product development program takes emerging novel techniques, and develops them into innovative products .

Diagenode is a leading global provider of complete solutions for epigenetics research. It was acquired by Hologic, in march 2021. The company's latest innovations include a unique, full automation system and industry's most validated antibodies. Its goal is to build products with pride and the highest level of performance .

Cancer is the leading cause of death. every second person (49% of men and 45% of women) is expected to develop cancer during their lifetime. There is an unmet need to develop a single test that can screen any cancer type before symptoms appear. DNA methylation tools allow the detection of cancerous DNA from a sea of healthy cells .

Corbett Life Science Pty., Ltd. designs, manufactures, and internationally distributes instrumentation systems for the life sciences. The company offers Rotor-Gene, a DNA amplification system; CAS-1200, a PCR setup robot; the CAS-4200 and CAS-4800 precision liquid handling workstations; X-tractor Gene, a nucleic acid extraction system; Palm-Cycler, a gradient thermal cycler with a palmtop computer interface; and CorProtocol, a reagent for DNA preparation on the X-tractor Gene system. It also offers Vapor-Lock, a PCR encapsulation barrier; high resolution melt, a instrumentation that provides acute thermal and optical precision, high speed data acquisition, and new software tools for data analysis used for gene scanning, sequence matching, genotyping, quantitative allelotyping, and quantitative DNA methylation analysis; and the Gel-Scan 3000, a automated DNA sequencer and fragment analyzer. In addition, the company provides automation for RNA/DNA extraction, liquid handling robotics, and real time DNA amplification and analysis to laboratories across the United States. It has operation in North America, South America, the United Kingdom, Europe, the Middle East, Africa, Asia, and Oceania. The company has a strategic partnership with Sigma-Aldrich. Corbett Life Science Pty. Ltd. was formerly known as Bio-Molecular Holdings Pty. Limited. Corbett Life Science Pty., Ltd. was founded in 1988 and is based in Sydney, Australia. It has operating units in Sydney and Brisbane, Australia; Cambridgeshire, the United Kingdom; and San Francisco, the United States. As of July 1, 2008, Corbett Life Science Pty., Ltd. operates as a subsidiary of Qiagen NV.

DNA Methylation

What is DNA Methylation?

Similar technologies

Epigenomics

Active Motif

Active Motif

Genpathway, Inc.

Roche NimbleGen

Kainos Medicine

Active Motif, Inc.

Diagenode

Enrich Bioscience

Corbett Life Science